Live
Endpoints NewsNovo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial execBioPharma DivePharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?Lonza NewsStipple Bio taps Lonza platform to advance ADC pipeline - The Pharma LetterCellSingle-cell mapping of regulatory DNA-protein interactionsCellPlasma signals of lung tumor promotion for molecular cancer preventionCellDeep learning of functional perturbations from condensate morphologyFierceBiotechAt first public hearing for FDA’s CNPV program, industry support meets ‘deep concern’ from expertsLonza NewsStipple Bio taps Lonza platform to advance ADC pipeline - The Pharma Letter10x Genomics Blog10x Genomics Stock On Fire: Up 41% With 8-Day Winning Streak - TrefisLabiotechEpisode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech mediaLonza NewsLonza and Stipple Bio partner to advance next-generation precision oncology ADC therapies - Indian Pharma PostEli LillyGilead, Merck, Eli Lilly lead $106B biopharma takeover wave in 2026 - MSN
PharmaVoice 8 janv. 2026

Billionaire Sean Parker has already shaken up cancer R&D. Can his nonprofit fix the funding gap?

Billionaire Sean Parker has already shaken up cancer R&D. Can his nonprofit fix the funding gap?

Original
Contenu indisponible. Consultez la source originale.